Cargando…

Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs

Platinum(iv) prodrugs are a promising class of anticancer agents designed to overcome the limitations of conventional platinum(ii) therapeutics. In this work, we present oxaliplatin(iv)-based complexes, which upon reduction, release acetylsalicylic acid (aspirin), known for its antitumor activity ag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kastner, Alexander, Mendrina, Theresa, Bachmann, Florian, Berger, Walter, Keppler, Bernhard K., Heffeter, Petra, Kowol, Christian R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Royal Society of Chemistry 2023
Materias:	Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334471/ https://www.ncbi.nlm.nih.gov/pubmed/37440920 http://dx.doi.org/10.1039/d3qi00968h

Ejemplares similares

Structure–Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands
por: Fronik, Philipp, et al.
Publicado: (2021)

A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance
por: Fronik, Philipp, et al.
Publicado: (2022)

Influence of the Fatty Acid Metabolism on the Mode of Action of a Cisplatin(IV) Complex with Phenylbutyrate as Axial Ligands
por: Mendrina, Theresa, et al.
Publicado: (2023)

Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo
por: Schueffl, Hemma, et al.
Publicado: (2021)

An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo
por: Mayr, Josef, et al.
Publicado: (2017)

EGFR-targeting peptide-coupled platinum(IV) complexes
por: Mayr, Josef, et al.
Publicado: (2017)

Multi-scale imaging of anticancer platinum(iv) compounds in murine tumor and kidney
por: Legin, A. A., et al.
Publicado: (2016)

Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib
por: Bielec, Bjoern, et al.
Publicado: (2020)

Synthesis, Characterization and in vitro Studies of a Cathepsin B‐Cleavable Prodrug of the VEGFR Inhibitor Sunitinib
por: Karnthaler‐Benbakka, Claudia, et al.
Publicado: (2018)

Liposomal formulations of anticancer copper(ii) thiosemicarbazone complexes
por: Mathuber, Marlene, et al.
Publicado: (2021)

Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
por: Huang, Jingjing, et al.
Publicado: (2022)

Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs
por: Mathuber, Marlene, et al.
Publicado: (2020)

A Dogma in Doubt: Hydrolysis of Equatorial Ligands of Pt(IV) Complexes under Physiological Conditions
por: Kastner, Alexander, et al.
Publicado: (2019)

Structure elucidation and quantification of the reduction products of anticancer Pt(iv) prodrugs by electrochemistry/mass spectrometry (EC-MS)
por: Frensemeier, L. M., et al.
Publicado: (2018)

Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity
por: Khoury, Aleen, et al.
Publicado: (2022)

Pt(IV) Prodrugs with NSAIDs as Axial Ligands
por: Spector, Daniil, et al.
Publicado: (2021)

Induction of targeted necrosis with HER2-targeted platinum(iv) anticancer prodrugs
por: Wong, Daniel Yuan Qiang, et al.
Publicado: (2015)

Potent Chlorambucil-Platinum(IV) Prodrugs
por: Aputen, Angelico D., et al.
Publicado: (2022)

Improving the anticancer activity of platinum(iv) prodrugs using a dual-targeting strategy with a dichloroacetate axial ligand
por: Liu, Fengfan, et al.
Publicado: (2019)

Combination of Drug Delivery Properties of PAMAM Dendrimers and Cytotoxicity of Platinum(IV) Complexes—A More Selective Anticancer Treatment?
por: Lerchbammer-Kreith, Yvonne, et al.
Publicado: (2023)

The impact of whole human blood on the kinetic inertness of platinum(iv) prodrugs – an HPLC-ICP-MS study
por: Theiner, Sarah, et al.
Publicado: (2018)

Development of a cobalt(iii)-based ponatinib prodrug system
por: Mathuber, Marlene, et al.
Publicado: (2021)

Human serum albumin as a copper source for anticancer thiosemicarbazones
por: Schaier, Martin, et al.
Publicado: (2023)

The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation
por: Baier, Dina, et al.
Publicado: (2022)

Impact of Stepwise NH(2)-Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance Circumvention
por: Kowol, Christian R., et al.
Publicado: (2016)

Prodrugs of NSAIDs: A Review
por: Shah, Kamal, et al.
Publicado: (2017)

Repurposing Platinum(IV) Prodrugs to Modulate Mitochondrial Metabolism
por: Zacharioudakis, Emmanouil, et al.
Publicado: (2023)

Behavior of platinum(iv) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation†
por: Schreiber-Brynzak, Ekaterina, et al.
Publicado: (2016)

The Lipid Metabolism as Target and Modulator of BOLD‐100 Anticancer Activity: Crosstalk with Histone Acetylation
por: Baier, Dina, et al.
Publicado: (2023)

NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer
por: Trondl, Robert, et al.
Publicado: (2012)

Cell-permeable lanthanide–platinum(iv) anti-cancer prodrugs
por: Yao, Kezi, et al.
Publicado: (2021)

The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects
por: Berasaluce, Iker, et al.
Publicado: (2019)

Biological activity of Pt(IV) prodrugs triggered by riboflavin-mediated bioorthogonal photocatalysis
por: Alonso-de Castro, Silvia, et al.
Publicado: (2018)

Platinum(IV)-Loaded Degraded Glycol Chitosan as Efficient Platinum(IV) Drug Delivery Platform
por: Lerchbammer-Kreith, Yvonne, et al.
Publicado: (2023)

Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling
por: Miklos, Walter, et al.
Publicado: (2016)

In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent
por: Olszewski, Ulrike, et al.
Publicado: (2009)

Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones
por: Pelivan, Karla, et al.
Publicado: (2018)

Versatile Platinum(IV) Prodrugs of Naproxen and Acemetacin as Chemo-Anti-Inflammatory Agents
por: Aputen, Angelico D., et al.
Publicado: (2023)

Self-assembly nanoplatform of platinum (Ⅳ) prodrug for enhanced ovarian cancer therapy
por: Ma, Xiao, et al.
Publicado: (2023)

Cetuximab-decorated and NIR-activated Nanoparticles Based on Platinum(IV)-prodrug: Preparation, Characterization and In-vitro Anticancer Activity in Epidermoid Carcinoma Cells
por: Wang, Yu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9n3shrn8cebqhd4rifsiudf0c5